Publications

Authors:

Ferrucci, Silvia; Tavecchio, Simona; Alberto Maronese, Carlo; Balato, Anna; Veronica Di Brizzi, Eugenia; Ortoncelli, Michela; Ribero, Simone; Girolomoni, Giampiero; Maurelli, Martina; Belloni Fortina, Anna; Caroppo, Francesca; Naldi, Luigi; Pezzolo, Elena; Nettis, Eustachio; Pugliese, Francesco; Stingeni, Luca; Hansel, Katharina; Rubegni, Giovanni; Calabrese, Laura; Russo, Filomena; Gola, Massimo; Magnaterra, Elisabetta; Rongioletti, Franco; Raffaele Mercuri, Santo; Paolino, Giovanni; Savoia, Paola; Veronese, Federica; Foti, Caterina; Ambrogio, Francesca; Scalvenzi, Massimiliano; Napolitano, Maddalena; Patruno, Cataldo; Dastoli, Stefano; Corazza, Monica; Borghi, Alessandro; Giacomo Calzavara-Pinton, Pier; Rossi, Mariateresa; Offidani, Annamaria; Radi, Giulia; Bonzano, Laura; Ferreli, Caterina; Piras, Viviana; Satta, Rosanna; Sucato, Federica; Piergiorgio Malagoli, 27; Francesca Gaiani, 28; Micali, Giuseppe; Letizia Musumeci, Maria; Concetta Fargnoli, Maria; Esposito, Maria; Grieco, Teresa; Chello, Camilla; Casazza, Giovanni; Valerio Marzano, Angelo

Title:

Short-, mid- and long-term efficacy of dupilumab in moderate-to-severe atopic dermatitis: a real-world multicentre Italian study of 2576 patients

Year:

2025

Type of item:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Language:

Inglese

Referee:

No

Name of journal:

Clinical and Experimental Dermatology

ISSN of journal:

0307-6938

Page numbers:

1561-1572

Keyword:

Atopic dermatitis, Dupilumab, short- mid- and long-term efficacy

Short description of contents:

Background The efficacy and safety of dupilumab in atopic dermatitis (AD) have been defined in clinical trials but limited real-world evidence on long-term treatment outcomes is currently available to inform clinical decisions. Objectives To describe the long-term effectiveness and safety of dupilumab up to 48 months in patients with moderate-to-severe AD. Methods A multicentre, retrospective, dynamic cohort study was conducted to assess long-term effectiveness and safety of dupilumab in patients with moderate-to-severe AD in a real-world setting. Predictors of minimal disease activity (MDA) optimal treatment target criteria [defined as the simultaneous achievement of a 90% reduction in Eczema Area and Severity Index score, itch-numeric rating scale (NRS) score≤1, sleep-NRS score≤1 and Dermatology Life Quality Index≤1] were investigated. Results In total, 2576 patients were enrolled from June 2018 to July 2022. MDA optimal treatment target criteria were achieved by 506/2309 (21.9%), 769/1959 (39.3%), 628/1247 (50.4%), 330/596 (55.4%) and 58/106 (54.7%) of those that reached 4, 12, 24, 36 and 48 months of follow-up, respectively. Logistic regression revealed a negative effect on MDA achievement for conjunctivitis and food allergy at all timepoints. Adverse events (AEs) were mild and were observed in 373/2364 (15.8%), 166/2066 (8.0%), 83/1291 (6.4%), 27/601 (4.5%) and 5/110 (4.5%) of those that reached 4, 12, 24, 36 and 48 months of follow-up. Conjunctivitis was the most frequently reported AE during the available follow-up. AEs led to treatment discontinuation in<1% of patients during the evaluated time periods. Conclusions The high long-term effectiveness and safety of dupilumab were confirmed in this dynamic cohort of patients with moderate-tosevere AD, regardless of clinical phenotype and course (persisting or relapsing) at baseline. Further research will be needed to investigate the effect of T helper cell 2 comorbidities and disease duration on the response to dupilumab and other newer therapeutics for AD.

Product ID:

144734

Handle IRIS:

11562/1157627

Last Modified:

March 19, 2025

Bibliographic citation:

Ferrucci, Silvia; Tavecchio, Simona; Alberto Maronese, Carlo; Balato, Anna; Veronica Di Brizzi, Eugenia; Ortoncelli, Michela; Ribero, Simone; Girolomoni, Giampiero; Maurelli, Martina; Belloni Fortina, Anna; Caroppo, Francesca; Naldi, Luigi; Pezzolo, Elena; Nettis, Eustachio; Pugliese, Francesco; Stingeni, Luca; Hansel, Katharina; Rubegni, Giovanni; Calabrese, Laura; Russo, Filomena; Gola, Massimo; Magnaterra, Elisabetta; Rongioletti, Franco; Raffaele Mercuri, Santo; Paolino, Giovanni; Savoia, Paola; Veronese, Federica; Foti, Caterina; Ambrogio, Francesca; Scalvenzi, Massimiliano; Napolitano, Maddalena; Patruno, Cataldo; Dastoli, Stefano; Corazza, Monica; Borghi, Alessandro; Giacomo Calzavara-Pinton, Pier; Rossi, Mariateresa; Offidani, Annamaria; Radi, Giulia; Bonzano, Laura; Ferreli, Caterina; Piras, Viviana; Satta, Rosanna; Sucato, Federica; Piergiorgio Malagoli, 27; Francesca Gaiani, 28; Micali, Giuseppe; Letizia Musumeci, Maria; Concetta Fargnoli, Maria; Esposito, Maria; Grieco, Teresa; Chello, Camilla; Casazza, Giovanni; Valerio Marzano, Angelo, Short-, mid- and long-term efficacy of dupilumab in moderate-to-severe atopic dermatitis: a real-world multicentre Italian study of 2576 patients «Clinical and Experimental Dermatology» , 2025 , pp. 1561-1572

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo